Neurologix, Inc. (OTCBB: NRGX) announced several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC). Recently completed analysis of new data showed patients treated with NLX-P101 had significantly increased "ON" times, or periods in which the symptoms of PD are best controlled, compared to sham subjects over the course of 12 months following treatment (p
Recent Posts
- Young People Asked How They Would Change Wales
- Fat Fuels Inflammation Killer, Research Shows
- Innovative £1.9 Million Partnership To End Mental Health Discrimination In Wales
- Typing Test Reveals Key Information About Cognitive Illusions
- Heart Disease Risk In Older Men May Be Increased By PTSD
- Health Care Coalition, National Quality Forum Endorse 30 'Safe Practices' All Hospitals Should Adopt To Prevent Patient Injury, Death
- Pacira Pharmaceuticals Presents New Data From EXPAREL Phase 3 Study At Orthopaedic Research Society's 57th Annual Meeting
- North Carolina Physicians Raise Concern Over Undocumented Immigrants' Lack Of Trust In Medical System
- New Jersey Confirms First Human Case Of West Nile Virus
- Buckley Receives 2010 ASHP-ABHP Leadership Award
- Care In First 6 Months Post Stroke Soars To More Than $2.5 Billion Annually